Your session is about to expire
← Back to Search
Other
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 20 Other Conditions
No Placebo-Only Group
Summary
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
Eligible Conditions
- Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: BMS-986165 and cyclosporineExperimental Treatment2 Interventions
BMS-986165 and cyclosporine administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
Not yet FDA approved
Cyclosporine
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,099,017 Total Patients Enrolled
39 Trials studying Psoriasis
21,454 Patients Enrolled for Psoriasis